Shanghai Junshi Biosciences Co's ROE % for the quarter that ended in Dec. 2025 was -13.89%. Shanghai Junshi Biosciences Co's PB Ratio for the quarter that ended in Dec. 2025 was 3.68.
Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -3.77%.
Shanghai Junshi Biosciences Co ROE % Adjusted to Book Value Related Terms
Shanghai Junshi Biosciences Co ROE % Adjusted to Book Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co ROE % Adjusted to Book Value Chart
SHJBF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -3.77% mean?
Shanghai Junshi Biosciences Co (SHJBF) has a ROE % Adjusted to Book Value of -3.77% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Junshi Biosciences Co and its competitors.
Is Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value too high?
Shanghai Junshi Biosciences Co's current ROE % Adjusted to Book Value is -3.77%. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value compare to VRTX and REGN?
Shanghai Junshi Biosciences Co's ROE % Adjusted to Book Value of -3.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Junshi Biosciences Co and its competitors. Shanghai Junshi Biosciences Co's current ROE % Adjusted to Book Value is -3.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (SHJBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.63, compared to a current price of $3.35 — trading 40.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -3.77%. Shanghai Junshi Biosciences Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current ROE % Adjusted to Book Value is -3.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 40.5% below its estimated GF Value™ of $5.63.
GuruFocus considers Shanghai Junshi Biosciences Co to be Significantly Undervalued.
Key valuation signals for SHJBF:
ROE % Adjusted to Book Value: -3.77%
GF Value™: $5.63 vs. price of $3.35 (40.5% below fair value)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
66GF Score
Get the complete analysis for SHJBF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
